Production (Stage)
MiNK Therapeutics, Inc.
INKT
$7.26
-$0.035-0.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 57.11% | -30.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -134.66% | |||
| Total Operating Expenses | -42.01% | 131.74% | |||
| Operating Income | 42.01% | -131.74% | |||
| Income Before Tax | -12.33% | -36.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.33% | -36.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.33% | -36.34% | |||
| EBIT | 42.01% | -131.74% | |||
| EBITDA | 41.73% | -133.79% | |||
| EPS Basic | -12.10% | -36.21% | |||
| Normalized Basic EPS | 36.80% | -126.93% | |||
| EPS Diluted | 44.03% | -172.80% | |||
| Normalized Diluted EPS | 36.80% | -126.93% | |||
| Average Basic Shares Outstanding | 0.20% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.20% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||